According to Immatics's latest financial reports and stock price the company's current price-to-sales ratio (TTM) is 17.5202. At the end of 2023 the company had a P/S ratio of 15.2.
Year | P/S ratio | Change |
---|---|---|
2023 | 15.2 | 328.92% |
2022 | 3.53 | -83.23% |
2021 | 21.1 | 12.9% |
2020 | 18.7 |
Company | P/S ratio | P/S ratio differencediff. | Country |
---|---|---|---|
Nymox Pharmaceutical NYMX | N/A | N/A | Bahamas |
NRC Health
NRC | 5.43 | -69.00% | ๐บ๐ธ USA |